SCHEDULING STATUS :
PROPRIETARY NAME :
(and dosage form)
Each tablet contains 500 mg hydrotalcite.
Each 5 mL of suspension contains 500 mg hydrotalcite
(preservative: bronopol 0,02% m/v).
PHARMACOLOGICAL CLASSIFICATION :
PHARMACOLOGICAL ACTION :
Hydrotalcite adjusts stomach acidity to within the optimum range of pH 3,0 - 5,0 whilst at the same time inhibiting pepsin activity.
Acid-pepsin disorders, peptic ulceration, gastritis, dyspepsia, hyper-acidity, 'heartburn' associated with reflux oesophagitis and hiatus hernia.
DOSAGE AND DIRECTIONS FOR USE:
Adults: 1 to 2 tablets to be chewed slowly and swallowed, or 1 to 2 medicine measuresful to be taken between meals.
Children : (Age 6 - 12 years) ½-1½ tablets or ½ -1½ medicine measuresful.
SIDE-EFFECTS AND SPECIAL PRECAUTIONS:
Occasional nausea and/or diarrhoea.
KNOWN SYMPTOMS OF OVERDOSAGE AND PARTICULARS OF ITS TREATMENT:
No acute or lasting effects of overdosage are to be expected.
Tablets : White 15 mm cylindrical, flat bevelled edge tablet flavoured with buttermint, marked altaciteon one side and rousselon the reverse.
Suspension : An aqueous suspension, slightly off-white, viscous and flavoured with buttermint.
White buttermint flavoured tablets marked 'altacitein packs of 30s and 100s, and a 200 mL bottle of white buttermint flavoured suspension.
Store in a cool dry place, below 25°C.
Keep out of reach of children.
REGISTRATION NUMBER :
NAME AND BUSINESS ADDRESS OF THE APPLICANT:
Roussel Laboratories (Pty) Limited
REG. NO. 66/01057/07
5th Street, Marlboro Ext.1, Sandton 2199.
DATE OF PUBLICATION OF THIS PACKAGE INSERT:
26th March 1979
SAEPI HOME PAGE
TRADE NAME INDEX
GENERIC NAME INDEX
Information presented by Malahyde Information Systems © Copyright 1996-2000